Ambu A S Ord (AMBFF) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Ambu A/s Class B.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.037 Hello everyone and welcome to today's conference call with AMBU where we are going 00:00:05.037 -- 00:00:09.102 to announce and talk about our results from Q2 00:00:09.102 -- 00:00:13.305 and the first half of our fiscal year 24-25. 00:00:13.688 -- 00:00:18.754 My name is Britt Milby Jensen, I'm the CEO of AMBU and with me today I have the 00:00:18.754 -- 00:00:22.659 pleasure of introducing Henrik Skagbender, our CFO. 00:00:22.659 -- 00:00:27.464 We will start with the presentation of the results and then we will open up the floor 00:00:27.464 -- 00:00:29.157 for questions. 00:00:29.157 -- 00:00:34.560 But let me start with the highlights and the key messages that we have. 00:00:34.562 -- 00:00:39.527 If we look at the first half of our fiscal year, we delivered a solid organic revenue 00:00:39.527 -- 00:00:44.572 growth, bringing our first half of the year up to a total 00:00:44.572 -- 00:00:49.056 organic revenue growth of 15.4%. This 00:00:49.056 -- 00:00:52.079 is in line with our own expectations 00:00:52.079 -- 00:00:56.933 and in line with our adjusted guidance from January. 00:00:56.933 -- 00:01:02.704 Also, we had a strong start on our very important launch, Ambul 00:01:02.704 -- 00:01:07.814 SureSight Connect, and we continue good momentum on our urology launches 00:01:07.814 -- 00:01:13.545 when it comes to our Ascope 5 Cysto HD and our ureteroscope. 00:01:13.545 -- 00:01:16.846 I will come back later and talk about these launches. 00:01:16.846 -- 00:01:23.034 Then we continue a strong EBIT margin where we have 15.2% 00:01:23.034 -- 00:01:24.656 EBIT 00:01:24.656 -- 00:01:29.723 growth in the first half of the year. And then last but not least, today we 00:01:29.723 -- 00:01:34.890 confirm our guidance that we came with...